An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia

Molecular Psychiatry

Volumn 13, Issue 11, 2008, Pages 1060-1068

  Jungerius, B J ^a   Hoogendoorn, M L C ^a   Bakker, S C ^a   Van't Slot, R ^a   Bardoel, A F ^a   Ophoff, R A ^a,b,c   Wijmenga, C ^a,d   Kahn, R S ^a   Sinke, R J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

22q11; Myelin; Oligodendrocyte; PIK4CA; Schizophrenia; White matter

Indexed keywords

MYELIN;

ARTICLE; CHROMOSOME 22Q; CHROMOSOME DELETION; CONTROLLED STUDY; GENE; HUMAN; MAJOR CLINICAL STUDY; PIK4CA GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RISK; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 22; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MYELIN PROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 54249159580     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002080     Document Type: Article

References (57)

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187-1192.
2. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000; 47: 210-220.
3. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-419.
4. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456.
5. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992; 49: 921-926.
6. Buchanan RW, Vladar K, Barta PE, Pearlson GD. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998; 155: 1049-1055.
7. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia relationship to negative symptoms. Arch Gen Psychiatry 2000; 57: 471-480.
8. Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 2001; 158: 234-243.
9. Staal WG, Hulshoff Pol HE, Schnack HG, Hoogendoorn ML, Jellema K, Kahn RS. Structural brain abnormalities in patients with schizophrenia and their healthy siblings. Am J Psychiatry 2000; 157: 416-421.
10. van Haren NE, Picchioni MM, McDonald C, Marshall N, Davis N, Ribchester T et al. A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia. Biol Psychiatry 2004; 56: 454-461.
11. Hof PR, Haroutunian V, Friedrich Jr VL, Byne W, Buitron C, Perl DP et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075-1085.
12. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597-610.
13. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 2004; 56: 41-45.
14. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
15. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mirnics K. Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochem Res 2002; 27: 1049-1063.
16. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456.
17. Lehrmann E, Hyde TM, Vawter MP, Becker KG, Kleinman JE, Freed WJ. The use of microarrays to characterize neuropsychiatric disorders: postmortem studies of substance abuse and schizophrenia. Curr Mol Med 2003; 3: 437-446.
18. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
19. Abstracts of the XIth World Congress of Psychiatric Genetics. Quebec City, Canada, October 4-8, 2003. 1. Am J Med Genet B Neuropsychiatr Genet 2003; 122: 1-190.
20. Bakker SC, Hoogendoorn MLC, Hendriks J, Verzijlbergen K, Caron S, Verduijn W et al. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 2007; 6: 113-119.
21. KEGG pathway for the PI-signaling system. http://www.genome.jp/dbget-bin/ show_pathway?hsa04070+5294.
22. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genomewide association studies. Nat Genet 2006; 38: 209-213.
23. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615-623.
24. Campbell CD, Ogburn EL, Lunetta KL, Lyon HN, Freedman ML, Groop LC et al. Demonstrating stratification in a European American population. Nat Genet 2005; 37: 868-872.
25. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
26. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
27. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217-1223.
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
29. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
30. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. Oxford University Press: New York, 1989.
31. Pearce N. Analytical implications of epidemiological concepts of interaction. Int J Epidemiol 1989; 18: 976-980.
32. Saito T, Stopkova P, Diaz L, Papolos DF, Boussemart L, Lachman HM. Polymorphism screening of PIK4CA: possible candidate gene for chromosome 22q11-linked psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 2003; 116: 77-83.
33. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998; 20: 70-73.
34. DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW et al. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 803-812.
35. Sullivan PF. The genetics of schizophrenia. PLoS Med 2005; 2: e212.
36. Murphy KC, Owen MJ. Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. Br J Psychiatry 2001; 179: 397-402.
37. Saito T, Guan F, Papolos DF, Rajouria N, Fann CS, Lachman HM. Polymorphism in SNAP29 gene promoter region associated with schizophrenia. Mol Psychiatry 2001; 6: 193-201.
38. Wonodi I, Hong LE, Avila MT, Buchanan RW, Carpenter Jr WT, Stine OC et al. Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res 2005; 78: 339-341.
39. Rozycka M, Lu YJ, Brown RA, Lau MR, Shipley JM, Fry MJ. cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 1998; 54: 569-574.
40. Misawa H, Ohtsubo M, Copeland NG, Gilbert DJ, Jenkins NA, Yoshimura A. Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem Biophys Res Commun 1998; 244: 531-539.
41. Tornieri K, Welshhans K, Geddis MS, Rehder V. Control of neurite outgrowth and growth cone motility by phosphatidylinositol-3-kinase. Cell Motil Cytoskeleton 2006; 63: 173-192.
42. Eberhard DA, Cooper CL, Low MG, Holz RW. Evidence that the inositol phospholipids are necessary for exocytosis. Loss of inositol phospholipids and inhibition of secretion in permeabilized cells caused by a bacterial phospholipase C and removal of ATP. Biochem J 1990; 268: 15-25.
43. Hinchliffe KA, Irvine RF, Divecha N. Aggregation-dependent, integrin-mediated increases in cytoskeletally associated PtdInsP2 (4,5) levels in human platelets are controlled by translocation of PtdIns 4-P 5-kinase C to the cytoskeleton. EMBO J 1997; 15: 6516-6524.
44. Cremona O, De Camilli P. Phosphoinositides in membrane traffic at the synapse. J Cell Sci 2001; 114(Part 6): 1041-1052.
45. Stopkova P, Vevera J, Paclt I, Zukov I, Papolos DF, Saito T et al. Screening of PIP5K2A promoter region for mutations in bipolar disorder and schizophrenia. Psychiatr Genet 2005; 15: 223-227.
46. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456.
47. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269-275.
48. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007; 10: 537-545.
49. Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F et al. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat Genet 1995; 11: 321-324.
50. Paunio T, Ekelund J, Varilo T, Parker A, Hovatta I, Turunen JA et al. Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. Hum Mol Genet 2001; 10: 3037-3048.
51. Sklar P, Pato MT, Kirby A, Petryshen TL, Medeiros H, Carvalho C et al. Genome-wide scan in Portuguese Island families identifies 5q31-5q35 as a susceptibility locus for schizophrenia and psychosis. Mol Psychiatry 2004; 9: 213-218.
52. Elleder M, Jerabkova M, Befekadu A, Hrebicek M, Berna L, Ledvinova J et al. Prosaposin deficiency - a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics 2005; 36: 171-180.
53. Hiraiwa M, Campana WM, Mizisin AP, Mohiuddin L, O'Brien JS. Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 1999; 26: 353-360.
54. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, Valle D et al. Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet 2003; 73: 601-611.
55. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, Valle D et al. Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet 2004; 75: 204-219.
56. Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A et al. Convergent evidence for 2′,3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psych 2006; 63: 18-24.
57. Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci USA 2006; 103: 12469-12474.